## MAR 1 6 2004 C

## SEQUENCE LISTING

Ball, Kathryn L Lane, David P

<120> Methods and Means for Inhibition of CDK4 Activity

<130> CCI-007US

<140> US 09/180,269

<141> 1999-07-08

<150> PCT/GB97/01250

<151> 1997-05-08

<150> GB 9609521.1

<151> 1996-05-08

<150> GB 9621314.5

<151> 1996-10-09

<160> 28

<170> PatentIn Ver. 2.1

<210> 1

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 1

Met Ser Glu Pro Ala Gly Asp Val Arg Gln Asn Pro Cys Gly Ser Lys  $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$ 

Ala Cys Arg Arg 20

<210> 2

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 2

Lys Ala Cys Arg Arg Leu Phe Gly Pro Val Asp Ser Glu Gln Leu Ser 1 5 10 15

Arg Asp Cys Asp

20

```
<210> 3
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthesised
Ser Arg Asp Cys Asp Ala Leu Met Ala Gly Cys Ile Gln Glu Ala Arg
Glu Arg Trp Asn
<210> 4
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthesised
<400> 4
Arg Glu Arg Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly
                   5
.Asp Phe Ala Trp
<210> 5
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthesised
<400> 5
Gly Asp Phe Ala Trp Glu Arg Val Arg Gly Leu Gly Leu Pro Lys Leu
Tyr Leu Pro Thr
<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence: Synthesised
Leu Tyr Leu Pro Thr Gly Pro Arg Arg Gly Arg Asp Glu Leu Gly Gly
                                     10
Gly Arg Arg Pro
<210> 7
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthesised
Gly Gly Arg Arg Pro Gly Thr Ser Pro Ala Leu Leu Gln Gly Thr Ala
                                     10
Glu Glu Asp His
<210> 8
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthesised
<400> 8
Ala Glu Glu Asp His Val Asp Leu Ser Leu Ser Cys Thr Leu Val Pro
                                     10
                                                          15
Arg Ser Gly Glu
<210> 9
<211> 20
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthesised
<400> 9
Pro Arg Ser Gly Glu Gln Ala Glu Gly Ser Pro Gly Gly Pro Gly Asp
```

Ser Gln Gly Arg

<210> 10

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 10

Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg
1 5 10 15

Leu Ile Phe Ser 20

<210> 11

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 11

Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser 1 5 10 15

Lys Arg Lys Pro 20

<210> 12

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Motif

<400> 12

Arg Arg Leu Ile Phe

<210> 13

<211> 8

```
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Motif
<400> 13
Lys Arg Arg Leu Ile Phe Ser Lys
<210> 14
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> (2)..(3)
<223> Xaa may be any amino acid
<220>
<221> SITE
<222> 6, 8
<223> Xaa may be hydrophobic
<220>
<221> SITE
<222> 1, 9
<223> Residue may be absent or different, ie another
      amino acid
<220>
<223> Description of Artificial Sequence: General
      formula
<400> 14
Lys Xaa Xaa Arg Arg Xaa Phe Xaa Pro
<210> 15
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Carrier
     peptide
<400> 15
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
                                      10
```

```
<210> 16
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthesised
<400> 16
Pro Arg Ser Gly Glu Gln Ala Glu Gly Ser Pro Gly Gly Pro Gly Asp
Ser Gln Gly Arg
<210> 17
<211> 20
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthesised
<400> 17
Glu Gln Ala Glu Gly Ser Pro Gly Gly Pro Gly Asp Ser Gln Gly Arg
Lys Arg Arg Gln
             20
<210> 18
<211> 20
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthesised
Gly Ser Pro Gly Gly Pro Gly Asp Ser Gln Gly Arg Lys Arg Arg Gln
Thr Ser Met Thr
             20
<210> 19
<211> 20
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence: Synthesised
<400> 19
Gly Pro Gly Asp Ser Gln Gly Arg Lys Arg Arg Gln Thr Ser Met Thr
                                     10
Asp Phe Tyr His
<210> 20
<211> 20
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthesised
<400> 20
Ser Gln Gly Arg Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His
                                     10
Ser Lys Arg Arg
             20
<210> 21
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthesised
<400> 21
Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser
Lys Arg Lys Pro
             20
<210> 22
<211> 16
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthesised
<400> 22
Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser Lys Arg Lys Pro
```

```
<210> 23
<211> 8
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Truncated
      peptide
<400> 23
Lys Arg Arg Leu Ile Phe Ser Lys
<210> 24
<211> 36
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthesised
<400> 24
Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg
Leu Ile Phe Ser Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met
Lys Trp Lys Lys
         35
<210> 25
<211> 24
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthesised
<400> 25
Lys Arg Arg Leu Ile Phe Ser Lys Arg Gln Ile Lys Ile Trp Phe Gln
                  5
Asn Arg Arg Met Lys Trp Lys Lys
             20
```

<210> 26 <211> 30

```
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthesised
Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Arg Gln
                                      10
Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
                                  25
<210> 27
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthesised
<400> 27
Gln Thr Ser Met Thr Asp Phe Tyr
<210> 28
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthesised
<400> 28
Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg
Leu Ile Phe Ser
             20
```